Reaction
Bladder Dysfunction reporting signals
As of the last recalculation, Bladder Dysfunction appears in 1,015 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is TOLTERODINE TARTRATE (PRR 23.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tolterodine Tartrate | 10 | 23.1 | 23.1 |
| Ocrelizumab | 55 | 19.2 | 19.2 |
| Fingolimod Hcl | 74 | 18.8 | 18.9 |
| Dalfampridine | 51 | 15.3 | 15.3 |
| Cladribine | 7 | 15.0 | 15.0 |
| Oxybutynin Chloride | 6 | 14.1 | 14.1 |
| Thiotepa | 6 | 13.0 | 13.0 |
| Fesoterodine Fumarate | 6 | 11.4 | 11.4 |
| Oxybutynin | 14 | 9.9 | 9.9 |
| Mirabegron | 18 | 9.7 | 9.7 |
| Natalizumab | 75 | 9.1 | 9.1 |
| Teriflunomide | 19 | 8.8 | 8.8 |
| Glatiramer Acetate | 24 | 8.4 | 8.4 |
| Ofatumumab | 13 | 8.1 | 8.1 |
| Interferon Beta-1B | 7 | 7.5 | 7.5 |
| Interferon Beta-1A | 65 | 7.3 | 7.3 |
| Siponimod | 3 | 6.9 | 6.9 |
| Botulinum Toxin Type A | 4 | 6.6 | 6.6 |
| Dimethyl Fumarate | 35 | 6.0 | 6.0 |
| Diroximel Fumarate | 3 | 5.2 | 5.2 |
| Peginterferon Beta-1A | 3 | 4.7 | 4.7 |
| Droxidopa | 3 | 2.9 | 2.9 |